The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 and older, including death.

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a live, weakened form of the virus to trigger immunity.

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment.